Content intended for healthcare professionals. By continuing, you confirm you are a HCP.
TBS · DXA
CE · FDA pending
Find bone fragility in the X-rays you already take
Turn existing imaging into opportunity. TBS Reveal™ analyses routine X-rays to surface bone-fragility risk, opportunistically identifying patients who may benefit from further bone-health assessment, before a first fracture.
Overview
Turn everyday X-rays into earlier answers
Osteoporosis often goes undetected until a fracture occurs. More than 70% of patients with fragility fractures are never tested or treated for osteoporosis1, and yet millions undergo routine X-rays every year for unrelated reasons.
Adding TBS® to routine X-rays (spine, chest, abdomen, or pelvis showing two or more lumbar vertebrae) TBS Reveal™ surfaces bone-fragility risk opportunistically, complementing — not replacing — established assessment pathways.
A routine X-ray, already taken
Bone fragility can be surfaced from ordinary X-rays
How it works
A single Bone Fragility Index, from a routine X-ray
1
Start with an X-ray
Any routine radiograph of the spine, chest, abdomen, or pelvis that includes two or more lumbar vertebrae. No new scan, no new visit.
2
AI + TBS analysis
Advanced image-feature analysis and AI combine bone mass (BMD) with Medimaps' patented TBS® technology to assess both bone quantity and quality.
3
A composite fragility index
The result is a single Bone Fragility Index that flags patients at very high risk for referral to confirmatory bone-health assessment.
The evidence
Validated across 18,858 radiographs and five clinical sites
A multinational study analysed 18,858 lumbar-spine radiographs with paired DXA scans from 11,138 adults across five clinical sites in Europe and the United States demonstrated consistent performance across internal, external, and ethnically diverse cohorts.2
0.83–0.86
AUC across all cohorts2
up to 90%
accuracy in external validation2
up to 96%
specificity across external cohorts2
11,138
adults · 5 global sites2
Clinically proven
TBS evidence keeps growing
2026 · eClinicalMedicine
Gatineau, G., De Gruttola, M., et al.
2026 · Archives of Osteoporosis
The Effects of Spaceflight Countermeasures on Trabecular Bone Score (TBS) of the Lumbar Spine
Anderson, K.D., Spector, E.R., et al.
2026 · Transplantation
Kratochvílová, S., Brunová, J, et al.
Integration
Zero workflow disruption, tailored to your needs
Seamlessly integrated with your PACS, TBS Reveal™ can automatically generate a Bone Fragility Assessment report. No new scan, no new visit.
One click
Access results directly in the same patient series with nothing new to check.
No additional radiation
TBS Reveal™ can read X-rays already captured for any clinical reason.
Smart reporting
Control frequency, tags, and scan selection to match your department's protocols.
Auto or manual
Run automatic analysis on eligible studies, or trigger it manually.
Flexible setup
Built for diverse IT environments.
The report
Bone Fragility Assessment for clinicians
TBS Reveal™ enables the automatic generation of reports powered by AI-driven analysis, supporting timely and informed decisions.
Instant report combines:
- Trabecular Bone Score (TBS®): A measure of bone quality microarchitecture.
-
Bone Fragility Index: Combines TBS® and bone mass (BMD) into one indicator.
- AI heatmap: Visual overlay highlighting areas of bone fragility.
- DICOM: Secondary capture and structured report options.
The report is seamlessly integrated into PACS for immediate access.
”
Routine X-rays are performed every day across healthcare systems, often in patients who may already have unrecognised bone fragility risk. TBS Reveal is designed to help turn these existing images into an opportunity for earlier identification.
Prof. Karen Hind
VP of Clinical Affairs, Research & Innovation, Medimaps
Book a demo
See TBS Reveal in action
Tell us a little about your setting and our clinical team will be in touch to arrange a personalised walkthrough.
Please don't include patient information (PHI). We'll respond within two business days.
TBS Reveal™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Reveal is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). FDA clearance is pending; TBS Reveal is not available for clinical use in the United States. Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.
References (2)
1. Compston, J (2020). Reducing the treatment gap in osteoporosis. The Lancet Diabetes & Endocrinology, 8(1), pp.p7–9. doi:https://doi.org/10.1016/s2213-8587(19)30378-x.
2. Gatineau, G., De Gruttola, M., Hind, K., Davies, M., Krueger, D., Binkley, N., Kužma, M., Payer, J., Guglielmi, G., Fahrleitner-Pammer, A., Chun, K., Bencardino, J., Sherman, A., Jones, K. and Hans, D. (2026). Validation of a deep learning model for bone fragility detection from conventional radiographs: An international cohort study. eClinicalMedicine, [online] 95, p.103974. doi:10.1016/j.eclinm.2026.103974.